IL2 and inflammatory bowel disease: Since Abatacept was not effective in clinical IBD trials, and here we observed a marked IL-2 blockage in the presence of Abatacept in WO-LPL, one could speculate that the presence of IL-2 in the lamina propria of patients with IBD is more important for regulation than inflammation.